These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 19770328

  • 1. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.
    Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B.
    AJR Am J Roentgenol; 2009 Oct; 193(4):1044-52. PubMed ID: 19770328
    [Abstract] [Full Text] [Related]

  • 2. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction.
    Kim S, Mannelli L, Hajdu CH, Babb JS, Clark TW, Hecht EM, Taouli B.
    J Magn Reson Imaging; 2010 Feb; 31(2):348-55. PubMed ID: 20099348
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging.
    Sahin H, Harman M, Cinar C, Bozkaya H, Parildar M, Elmas N.
    J Vasc Interv Radiol; 2012 Feb; 23(2):241-7. PubMed ID: 22019180
    [Abstract] [Full Text] [Related]

  • 4. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience.
    Mannelli L, Kim S, Hajdu CH, Babb JS, Taouli B.
    Eur J Radiol; 2013 Apr; 82(4):577-82. PubMed ID: 23246330
    [Abstract] [Full Text] [Related]

  • 5. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
    Kokabi N, Camacho JC, Xing M, Edalat F, Mittal PK, Kim HS.
    J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
    [Abstract] [Full Text] [Related]

  • 6. [Evaluation of the effect of transcatheter arterial chemoembolization in treatment of primary hepatocellular carcinoma with magnetic resonance diffusion-weighted imaging: 4-6-week follow-up of 25 cases].
    Fan WJ, Zhang L, Ouyang YS.
    Zhonghua Yi Xue Za Zhi; 2008 Sep 16; 88(35):2474-7. PubMed ID: 19080627
    [Abstract] [Full Text] [Related]

  • 7. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator?
    Goshima S, Kanematsu M, Kondo H, Yokoyama R, Tsuge Y, Shiratori Y, Onozuka M, Moriyama N.
    J Magn Reson Imaging; 2008 Apr 16; 27(4):834-9. PubMed ID: 18383261
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
    Xu PJ, Yan FH, Wang JH, Shan Y, Ji Y, Chen CZ.
    J Comput Assist Tomogr; 2010 Jul 16; 34(4):506-12. PubMed ID: 20657216
    [Abstract] [Full Text] [Related]

  • 10. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
    Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF.
    J Vasc Interv Radiol; 2006 Mar 16; 17(3):505-12. PubMed ID: 16567675
    [Abstract] [Full Text] [Related]

  • 11. [Comparison between pathological findings and MR diffusion-weighted imaging in primary hepatocellular carcinoma after transcatheter arterial chemoembolization].
    Xiao YP, Xiao EH, Luo JG, Bian DJ, Li MQ, He Z, Shang QL, Liang B.
    Zhonghua Zhong Liu Za Zhi; 2008 Dec 16; 30(12):914-6. PubMed ID: 19173992
    [Abstract] [Full Text] [Related]

  • 12. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.
    Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF.
    Radiology; 2014 Dec 16; 273(3):746-58. PubMed ID: 25028783
    [Abstract] [Full Text] [Related]

  • 13. [Role of magnetic resonance in the follow-up o hepatocarcinoma treated with percutaneous ethanol injection (PEI) or transarterial chemoembolization (TACE)].
    De Cobelli F, Castrucci M, Sironi S, Livraghi T, Venturini M, Salvioni M, Del Maschio A.
    Radiol Med; 1994 Dec 16; 88(6):806-17. PubMed ID: 7878241
    [Abstract] [Full Text] [Related]

  • 14. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma.
    Yuan Z, Ye XD, Dong S, Xu LC, Xu XY, Liu SY, Xiao XS.
    Eur J Radiol; 2010 Jul 16; 75(1):e9-14. PubMed ID: 19540083
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization.
    Kokabi N, Ludwig JM, Camacho JC, Xing M, Mittal PK, Kim HS.
    J Vasc Interv Radiol; 2015 Dec 16; 26(12):1777-86. PubMed ID: 26603497
    [Abstract] [Full Text] [Related]

  • 17. Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas.
    Yu JS, Kim JH, Chung JJ, Kim KW.
    J Magn Reson Imaging; 2009 Jul 16; 30(1):153-60. PubMed ID: 19557734
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.